Ocaliva warning could remove overhang on Intercept shares

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) announced the addition of a boxed warning to FDA's label of Ocaliva obeticholic acid stating that hepatic decompensation and failure can occur in incorrectly dosed primary biliary cholangitis (PBC) patients with Child-Pugh Class B

Read the full 382 word article

User Sign In